Abstract 360P
Background
Inetetamab is a neotype HER2-targeted monoclonal antibody with amino acids modified Fc segment which optimizes the antibody-dependent cellular cytotoxicity effect. However, robust evidence evaluating the combination of inetetamab combined with pertuzumab, paclitaxel and carboplatin (TCbIP) for neoadjuvant therapy is still lacking. This study aimed to evaluate the efficacy and safety of TCbIP as a neoadjuvant therapy for patients with locally advanced (LA) HER2-positive breast cancer.
Methods
This phase II trial included female patients with histologically confirmed stage IIA to IIIC HER2-positive primary invasive breast cancer. Eligible patients received TCbIP treatment every three weeks for a maximum of six cycles followed by surgery. The primary endpoint was pathologic complete response (pCR, ypT0/is ypN0) rate. Key secondary endpoints included near pCR (npCR, residual breast disease <1cm) rate, objective response rate (ORR) and safety.
Results
From November 2021 to May 2023, 28 patients were enrolled in the trial. One patient received one cycle of the study treatment and was lost to follow-up without surgery, and four patients received one cycle of the study treatment and were still in treatment, leaving 23 patients in the ITT population. Among these 23 patients (82.6% in stage III), 16 patients completed the study treatment and surgery (PP population) and six patients were still undergoing neoadjuvant treatment. The ORR was 91.3% (21/23) in the ITT population and 93.8% (15/16) in the PP population. Among the 16 patients in the PP population, 10 patients (62.5%) achieved pCR. A total of 14 patients (87.5%) achieved npCR. For patients with hormone receptor (HR) negative and positive tumors, the pCR rates were 88.9% (8/9) and 28.6% (2/7), respectively. The most common grade 3 adverse event was neutropenia (25.0%). No significant reduction in the left ventricular ejection fraction was observed in any patient.
Conclusions
Neoadjuvant therapy with TCbIP has shown promising efficacy and manageable toxicity in patients with HER2-positive LA breast cancer.
Clinical trial identification
NCT05749016.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Incidence and prognostic value of HER2-low expression metastatic breast cancer in Asian population: A 10-year retrospective study
Presenter: Thanate Dajsakdipon
Session: Poster session 03
435P - Phase II single arm study of durvalumab and olaparib (D+O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)
Presenter: Takeo Fujii
Session: Poster session 03
436P - Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial)
Presenter: Hui Cao
Session: Poster session 03
437P - Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app
Presenter: Bela Mrinakova
Session: Poster session 03
438P - Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 03
439P - Testing HR+ / HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
Presenter: Anastasios Boutis
Session: Poster session 03
440P - Palliative radiotherapy in metastatic breast cancer: Does molecular subtype predict patient response to radiotherapy?
Presenter: Meriem El Bessi
Session: Poster session 03
441P - Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study
Presenter: Achim Woeckel
Session: Poster session 03
442P - Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001)
Presenter: Federico Waisberg
Session: Poster session 03
443P - Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer
Presenter: Cengiz Karacin
Session: Poster session 03